|
| 1 |
|
Conditions listed in this trial |
|
|
Bladder Cancer |
|
|
Breast Cancer |
|
|
Carcinoma of Unknown Primary |
|
|
Esophageal Cancer |
|
|
Gastric Cancer |
|
|
Head and Neck Cancer |
|
|
Lung Cancer |
|
|
Melanoma (Skin) |
|
|
Ovarian Cancer |
|
|
Pancreatic Cancer |
|
|
Prostate Cancer |
|
|
Sarcoma |
|
| 2 |
|
Additional conditions recognized in this trial |
|
|
Breast Neoplasms |
|
|
Carcinoma |
|
|
Esophageal Diseases |
|
|
Esophageal Neoplasms |
|
|
Head and Neck Neoplasms |
|
|
Lung Neoplasms |
|
|
Melanoma |
|
|
Neoplasms, Unknown Primary |
|
|
Ovarian Neoplasms |
|
|
Pancreatic Neoplasms |
|
|
Prostatic Neoplasms |
|
|
Stomach Neoplasms |
|
|
Urinary Bladder Neoplasms |
|
| 3 |
|
More general conditions related to this trial |
|
|
Adnexal Diseases |
|
|
Breast Diseases |
|
|
Digestive System Diseases |
|
|
Digestive System Neoplasms |
|
|
Endocrine Gland Neoplasms |
|
|
Endocrine System Diseases |
|
|
Gastrointestinal Diseases |
|
|
Gastrointestinal Neoplasms |
|
|
Genital Diseases, Female |
|
|
Genital Diseases, Male |
|
|
Genital Neoplasms, Female |
|
|
Genital Neoplasms, Male |
|
|
Gonadal Disorders |
|
|
Lung Diseases |
|
|
Neoplasm Metastasis |
|
|
Neoplasms |
|
|
Neoplasms by Histologic Type |
|
|
Neoplasms by Site |
|
|
Neoplasms, Connective and Soft Tissue |
|
|
Neoplasms, Germ Cell and Embryonal |
|
|
Neoplasms, Glandular and Epithelial |
|
|
Neoplasms, Nerve Tissue |
|
|
Neoplastic Processes |
|
|
Neuroectodermal Tumors |
|
|
Neuroendocrine Tumors |
|
|
Nevi and Melanomas |
|
|
Ovarian Diseases |
|
|
Pancreatic Diseases |
|
|
Pathologic Processes |
|
|
Prostatic Diseases |
|
|
Respiratory Tract Diseases |
|
|
Respiratory Tract Neoplasms |
|
|
Skin Diseases |
|
|
Stomach Diseases |
|
|
Thoracic Neoplasms |
|
|
Urinary Bladder Diseases |
|
|
Urogenital Neoplasms |
|
|
Urologic Diseases |
|
|
Urologic Neoplasms |
|
| 4 |
|
Interventions listed in this trial |
|
|
docetaxel |
|
|
filgrastim |
|
|
gemcitabine hydrochloride |
|
| 5 |
|
Additional drug interventions recognized in this trial |
|
|
Gemcitabine |
|
| 6 |
|
More general drug interventions related to this trial |
|
|
Anti-Infective Agents |
|
|
Antimetabolites |
|
|
Antimetabolites, Antineoplastic |
|
|
Antineoplastic Agents |
|
|
Antiviral Agents |
|
|
Enzyme Inhibitors |
|
|
Immunologic Factors |
|
|
Immunosuppressive Agents |
|
|
Molecular Mechanisms of Pharmacological Action |
|
|
Pharmacologic Actions |
|
|
Physiological Effects of Drugs |
|
|
Radiation-Sensitizing Agents |
|
|
Therapeutic Uses |
|
| 7 |
|
Sponsors listed in this trial |
|
|
Norris Cotton Cancer Center |
|
|
National Cancer Institute (NCI) |
